Compare EE & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EE | COLL |
|---|---|---|
| Founded | 2003 | 2002 |
| Country | United States | United States |
| Employees | 1046 | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2022 | 2015 |
| Metric | EE | COLL |
|---|---|---|
| Price | $35.79 | $33.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $39.20 | ★ $51.40 |
| AVG Volume (30 Days) | 362.3K | ★ 428.8K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.96% | N/A |
| EPS Growth | ★ 0.79 | N/A |
| EPS | 0.37 | ★ 0.40 |
| Revenue | ★ $1,228,263,000.00 | $780,567,000.00 |
| Revenue This Year | $23.59 | $8.01 |
| Revenue Next Year | $24.37 | N/A |
| P/E Ratio | $97.89 | ★ $87.03 |
| Revenue Growth | ★ 44.26 | 23.62 |
| 52 Week Low | $21.29 | $28.34 |
| 52 Week High | $43.18 | $50.79 |
| Indicator | EE | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 55.89 | 43.91 |
| Support Level | $35.10 | $31.56 |
| Resistance Level | $43.18 | $36.22 |
| Average True Range (ATR) | 1.44 | 1.70 |
| MACD | 0.26 | 0.00 |
| Stochastic Oscillator | 80.54 | 16.17 |
Excelerate Energy Inc. offers comprehensive LNG solutions by providing integrated services throughout the LNG value chain. The company delivers a full range of regasification services, including Floating Storage and Regasification Units (FSRUs), infrastructure development, and the supply of LNG and natural gas. With operational presence in several countries - Argentina, Bangladesh, Brazil, Finland, Germany, Pakistan, the United Arab Emirates (UAE), and the United States. The company generates revenue through Terminal Services, as well as from LNG, gas, and power. These revenues are derived from its vertically integrated activities in LNG sourcing, transportation, regasification, and power generation.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.